EGFR and non-small cell lung carcinoma: Different survivals were observed for these different NSCLC subgroups: 3.51 years for EGFR-mutated patients; 2.9 years for ALK rearrangements; 2.3 years for KRAS-mutated patients; 2.2 years for those with other genetic abnormalities; 1.85 years for those without an actionable mutation.